サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726122

米国のバイオ分析検査サービス市場規模、シェア、動向分析レポート：分子別、検査別、ワークフロー別、最終用途別、セグメント別予測、2025年～2030年

U.S. Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule (Small Molecule, Large Molecule), By Test, By Workflow, By End-use (Pharma & BioPharma Companies, CDMO, CRO), And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
米国のバイオ分析検査サービス市場規模、シェア、動向分析レポート：分子別、検査別、ワークフロー別、最終用途別、セグメント別予測、2025年～2030年
出版日: 2025年04月01日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向

米国のバイオ分析検査サービス市場規模は、2024年に19億8,000万米ドルと推定され、2025～2030年にかけてCAGR 9.33％で成長すると予測されています。

米国の生物学的分析検査サービス産業の成長は、医薬品開発と承認プロセスの上昇、生物製剤、バイオシミラー、遺伝子治療の需要拡大、検査サービスのアウトソーシングの増加など、いくつかの要因によってもたらされます。さらに、厳しいFDA規制が精密なバイオ分析検査の必要性を高めています。さらに、生物学的分析検査施設の拡大も市場成長を促進する重要な側面です。

複数の産業企業やバイオ製薬会社は、先進的バイオ分析サービスに対する需要の高まりに対応するため、検査インフラのアップグレードと拡大に多額の投資を行っています。さらに、複雑な生物製剤、バイオシミラー、遺伝子治療、個別化医療開発の急増は、薬剤動態学、バイオマーカー探索、免疫原性評価などの複雑なバイオ分析を実行するための先進的検査プラットフォームの必要性をさらに高めています。

さらに、複数のサービスプロバイダが、高分解能質量分析（HRMS）、NGS、自動化技術を統合した最先端の施設を開発し、より迅速で正確、かつ費用対効果の高いバイオ分析検査を提供しており、開発をさらに促進しています。例えば、2024年9月、Laboratory Corporation of America Holdingsはグリーンフィールドにあるラボの拡大完了を発表しました。この拡大は、希少疾患、腫瘍学、その他の治療領域における細胞療法や遺伝子療法を含む先端治療のための前臨床と臨床分子生物学的分析検査サービスの開発と検証をサポートすることを目的としていました。この拡大は、同社に競合優位性をもたらしました。

バイオ分析検査の重要性に関する規制管理と意識の高まりは、バイオ分析検査サービス市場の成長を促進する主要因です。米国FDAやEMAなど複数の規制当局が医薬品開発、特に薬剤動態学、薬力学、生物学的同等性検査について厳格なガイドラインを導入したことが、アウトソーシング志向の高まりにつながっています。これらのガイドラインは、新薬やバイオシミラーの安全性と有効性を高めるために、正確で信頼性の高い生物学的分析法の必要性を強調しています。例えば、米国FDAのバイオ分析法バリデーション・ガイダンスは、分析法開発、バリデーション、サンプル分析に関する明確な基準を示しており、これが製薬企業が受託サービスプロバイダに専門知識を求める原動力となっています。さらに、市場参入企業は、先進的分析プラットフォームと標準化されたプロトコルを提供することで、スポンサーが規制要件に準拠するのを支援し、市場の需要を促進しています。

同様に、技術の進歩や研究開発投資の拡大も、米国の生物分析検査サービス産業の成長を促進する主要因です。高性能・スクリーニング（HTS）、液体クロマトグラフィー-質量分析（LC-MS）、次世代シーケンス（NGS）などの革新的技術の継続的開発により、バイオ分析検査の精度、スピード、感度が大幅に向上しています。これらの技術革新は、サービスプロバイダがより複雑な検査を実施し、医薬品の有効性、安全性、薬剤動態などに関する正確なデータを取得するのに役立っています。さらに、自動化と人工知能（AI）をバイオ分析ワークフローに統合することで、プロセスが合理化され、ヒューマンエラーが減少し、スループットが向上しました。このような要因が、推定期間にわたって市場を牽引すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のバイオ分析検査サービス市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助市場展望
  • 市場力学
    • 市場の促進要因分析
    • 市場抑制要因分析
  • 投資と資金調達の観点
  • 臨床検査件数分析（2024年）
    • 地域別臨床検査総数（2024年）
    • 臨床検査の総数（相別）（2024年）
    • 臨床検査の総数（研究デザイン別）（2024年）
    • 主要治療領域別臨床検査総数（2024年）
  • 価格モデル分析
  • 技術
  • 規制の枠組み
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • SWOT分析によるPESTEL
    • COVID-19の影響分析

第4章 米国のバイオ分析検査サービス市場：分子、推定・動向分析

  • 米国のバイオ分析検査サービス市場（分子別）：セグメントダッシュボード
  • 米国のバイオ分析検査サービス市場（分子別）：変動分析
  • 分子別、2018～2030年
  • 小分子
  • 巨大分子
    • LC-MS研究
    • 免疫測定
    • その他の巨大分子検査

第5章 米国のバイオ分析検査サービス市場：検査、推定・動向分析

  • 米国のバイオ分析検査サービス市場（検査別）：セグメントダッシュボード
  • 米国の生体分析検査サービス市場（検査別）：変動分析
  • 検査別、2018～2030年
  • ADME
    • 生体内
    • 体外
  • 薬剤動態（PK）
  • 薬力学（PD）
  • バイオアベイラビリティ
  • 生物学的同等性
  • バイオマーカー検査
  • 細胞ベースアッセイ
  • ウイルス検査
  • その他

第6章 米国のバイオ分析検査サービス市場：ワークフロー、推定・動向分析

  • 米国のバイオ分析検査サービス市場（ワークフロー別）：セグメントダッシュボード
  • 米国のバイオ分析検査サービス市場（ワークフロー別）：変動分析
  • ワークフロー別、2018～2030年
  • サンプルの収集と準備
    • サンプルの収集、取り扱い、保管
    • タンパク質沈殿
    • 液液抽出
    • 固相抽出
    • その他
  • 方法の開発と検証
  • サンプル分析
    • ハイフン技法
    • クロマトグラフィー技術
    • 電気泳動
    • リガンド結合アッセイ
    • 質量分析
    • 分光技術
    • ゲノムと分子技術
  • その他

第7章 米国のバイオ分析検査サービス市場：最終用途別、推定・動向分析

  • 米国のバイオ分析検査サービス市場（最終用途別）：セグメントダッシュボード
  • 米国のバイオ分析検査サービス市場、最終用途別：変動分析
  • 用途別、2018～2030年
  • 製薬・バイオ医薬品企業
  • CDMO
  • 最高経営責任者（CRO）
  • その他

第8章 競合情勢

  • 市場参入企業の分類
  • 企業市場シェア/評価分析、2024年
  • 企業プロファイル
    • Thermo Fisher Scientific, Inc.
    • ICON plc
    • Charles River Laboratories International, Inc.
    • Laboratory Corporation of America Holdings.
    • IQVIA Inc.
    • Syneos Health
    • SGS SA
    • Intertek Group Plc
    • Pace Analytical Services, LLC
    • Medpace Holdings, Inc.
    • North America Science Associates Inc.（NAMSA）
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Molecule, 2018 - 2030 (USD Million)
  • Table 3 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Large Molecule Tests, 2018 - 2030 (USD Million)
  • Table 4 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Large Molecule Immunoassay Tests, 2018 - 2030 (USD Million)
  • Table 5 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Test, 2018 - 2030 (USD Million)
  • Table 6 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by ADME Test, 2018 - 2030 (USD Million)
  • Table 7 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Workflow, 2018 - 2030 (USD Million)
  • Table 8 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Sample Collection and Preparation, 2018 - 2030 (USD Million)
  • Table 9 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Sample Analysis, 2018 - 2030 (USD Million)
  • Table 10 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Spectroscopic Techniques, 2018 - 2030 (USD Million)
  • Table 11 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by Genomic and Molecular Techniques, 2018 - 2030 (USD Million)
  • Table 12 U.S. Bioanalytical Testing Services Market Estimates and Forecasts, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Financial performance

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Bioanalytical Testing Services Market dynamics
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Bioanalytical Testing Services Market: Molecule Outlook and Key Takeaways
  • Fig. 20 U.S. Bioanalytical Testing Services Market: Molecule Movement Analysis
  • Fig. 21 Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Large Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 LC-MS Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Immunoassays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pharmacokinetics (PK) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 ADA Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Other Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Other Large Molecule Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Bioanalytical Testing Services Market: Test Outlook and Key Takeaways
  • Fig. 30 U.S. Bioanalytical Testing Services Market: Test Movement Analysis
  • Fig. 31 ADME Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 In-vivo Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 In-vitro Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Pharmacokinetics (PK) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Pharmacodynamics (PD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Bioavailability Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Bioequivalence Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Biomarker Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Cell-based Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Virology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Other Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Bioanalytical Testing Services Market: Workflow Outlook and Key Takeaways
  • Fig. 43 U.S. Bioanalytical Testing Services Market: Workflow Movement Analysis
  • Fig. 44 Sample Collection and Preparation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Sample Collection, Handling and Storage Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Protein Precipitation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Liquid-Liquid Extraction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Solid Phase Extraction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Method Development and Validation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Sample Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Hyphenated technique Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Chromatographic technique Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Electrophoresis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Ligand Binding Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Mass Spectrometry Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spectroscopic Techniques Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Nuclear Magnetic Resonance (NMR) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Genomic and Molecular Techniques Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Polymerase Chain Reaction (PCR) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Next-Generation Sequencing (NGS) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Other Processes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 U.S. Bioanalytical Testing Services Market: End Use outlook and key takeaways
  • Fig. 66 U.S. Bioanalytical Testing Services Market: End Use movement analysis
  • Fig. 67 Pharma & BioPharma Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 CRO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key company categorization
  • Fig. 72 Service heat map analysis
  • Fig. 73 Strategic framework
目次
Product Code: GVR-4-68040-292-0

Market Size & Trends:

The U.S. bioanalytical testing services market size was estimated at USD 1.98 billion in 2024 and is expected to grow at a CAGR of 9.33% from 2025 to 2030. The growth of the U.S. bioanalytical testing services industry is driven by several factors, such as the rising drug development and approval process, growing demand for biologics, biosimilars, and gene therapies, and rising outsourcing of testing services. In addition, Stringent FDA regulations are driving the need for precise bioanalytical testing. Furthermore, the expansion of bioanalytical testing facilities is another key aspect driving the market growth.

Several industry players and biopharmaceutical companies are investing significantly to upgrade and expand their testing infrastructure to meet the growing demand for advanced bioanalytical services. Moreover, a surge in the number of complex biologics, biosimilars, gene therapies, and personalized medicine development is further creating the need for sophisticated testing platforms to perform complex bioanalyses, such as pharmacokinetics, biomarker discovery, and immunogenicity assessments.

Moreover, several service providers are developing state-of-the-art facilities integrated with high-resolution mass spectrometry (HRMS), NGS, and automation technologies to offer faster, more accurate, and cost-effective bioanalytical testing, further propelling market progression. For instance, in September 2024, Laboratory Corporation of America Holdings announced the completion expansion of its laboratory in Greenfield. The expansion aimed to o support the development and validation of preclinical and clinical molecular bioanalytical testing services for advanced therapies, including cell and gene therapies for rare diseases, oncology, and other therapeutic areas. This expansion offered a competitive advantage to the firm.

Increasing regulatory control and awareness regarding the importance of bioanalytical testing are key factors propelling the growth of the bioanalytical testing service market. The introduction of stringent guidelines on drug development, particularly in pharmacokinetics, pharmacodynamics, and bioequivalence testing by several regulatory agencies, such as the U.S. FDA and EMA, leads to a rising preference for outsourcing. These guidelines highlight the need for precise and reliable bioanalytical methods to enhance the safety and efficacy of new drugs & biosimilars. For instance, the U.S. FDA's Bioanalytical Method Validation Guidance provides clear standards for method development, validation, and sample analysis, which have driven pharmaceutical companies to seek specialized expertise from contract service providers. Moreover, the market participants assist sponsors in complying with regulatory requirements by offering advanced analytical platforms and standardized protocols, driving market demand.

Likewise, technological advancements and growing R&D investments are key factors driving the U.S. bioanalytical testing service industry growth. The continuous developments of innovative technologies, such as High-Throughput Screening (HTS), Liquid Chromatography-Mass Spectrometry (LC-MS), and Next-generation Sequencing (NGS), have significantly enhanced the precision, speed, and sensitivity of bioanalytical testing. These innovations assist service providers in conducting more complex studies and gaining accurate data on drug efficacy, safety, and pharmacokinetics, among others. Moreover, integrating automation and Artificial Intelligence (AI) into bioanalytical workflows streamlined processes, reduced human error, and improved throughput. Such factors are anticipated to drive the market over the estimated period.

U.S. Bioanalytical Testing Services Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. bioanalytical testing services market report based on molecule, test, workflow, and end-use:

  • Molecule Outlook (Revenue, USD Million, 2018 - 2030)
  • Small Molecule
  • Large Molecule
    • LC-MS Studies
    • Immunoassays
    • Pharmacokinetics (PK)
    • ADA Assay
    • Other immunoassays
    • Other Large Molecule Tests
  • Test Outlook (Revenue, USD Million, 2018 - 2030)
  • ADME
    • In-vivo
    • In-vitro
  • Pharmacokinetics (PK)
  • Pharmacodynamics (PD)
  • Bioavailability
  • Bioequivalence
  • Biomarker Testing
  • Cell-based Assay
  • Virology Testing
  • Other Tests
  • Workflow Outlook (Revenue, USD Million, 2018 - 2030)
  • Sample Collection and Preparation
    • Sample Collection, Handling and Storage
    • Protein Precipitation
    • Liquid-Liquid Extraction
    • Solid Phase Extraction
    • Others
  • Method Development and Validation
  • Sample Analysis
    • Hyphenated Technique
    • Chromatographic Technique
    • Electrophoresis
    • Ligand Binding Assay
    • Mass Spectrometry
    • Spectroscopic Techniques
    • Nuclear Magnetic Resonance (NMR)
    • Others
    • Genomic and Molecular Techniques
    • Polymerase Chain Reaction (PCR)
    • Next-Generation Sequencing (NGS)
    • Others
  • Other Processes
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharma & BioPharma Companies
  • CDMO
  • CRO
  • Others

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule
    • 1.2.2. Test
    • 1.2.3. Workflow
    • 1.2.4. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Bioanalytical Testing Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological Advancements & Growing R&D Investments
      • 3.2.1.2. Regulatory Control and Increasing Awareness Regarding Bioanalytical Testing
      • 3.2.1.3. Expansion of Bioanalytical Testing Facilities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Data Security Concerns
  • 3.3. Investments & Funding Perspective
  • 3.4. Clinical Trials Volume Analysis, (2024)
    • 3.4.1. Total Number Of Clinical Trials By Region (2024)
    • 3.4.2. Total Number Of Clinical Trials, By Phase (2024)
    • 3.4.3. Total Number Of Clinical Trials, By Study Design (2024)
    • 3.4.4. Total Number Of Clinical Trials, By Key Therapeutic Area (2024)
  • 3.5. Pricing Model Analysis
  • 3.6. Technology Landscape
  • 3.7. Regulatory Framework
  • 3.8. Market Analysis Tools
    • 3.8.1. Porter's Five Force Analysis
    • 3.8.2. PESTEL by SWOT Analysis
    • 3.8.3. COVID-19 Impact Analysis

Chapter 4. U.S. Bioanalytical Testing Services Market: Molecule Estimates & Trend Analysis

  • 4.1. U.S. Bioanalytical Testing Services Market, By Molecule: Segment Dashboard
  • 4.2. U.S. Bioanalytical Testing Services Market, By Molecule: Movement Analysis
  • 4.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By Molecule, 2018 - 2030 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. LC-MS Studies
      • 4.5.2.1. LC-MS Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Immunoassays
      • 4.5.3.1. Immunoassays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.2. Pharmacokinetics (PK)
        • 4.5.3.2.1. Pharmacokinetics (PK) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.3. ADA Assay
        • 4.5.3.3.1. ADA Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.4. Other
        • 4.5.3.4.1. Other Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Other Large Molecule Tests
      • 4.5.4.1. Other Large Molecule Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Bioanalytical Testing Services Market: Test Estimates & Trend Analysis

  • 5.1. U.S. Bioanalytical Testing Services Market, By Test: Segment Dashboard
  • 5.2. U.S. Bioanalytical Testing Services Market, By Test: Movement Analysis
  • 5.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By Test, 2018 - 2030 (USD Million)
  • 5.4. ADME
    • 5.4.1. ADME Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. In-vivo
      • 5.4.2.1. In-vivo Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. In-vitro
      • 5.4.3.1. In-vitro Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Pharmacokinetics (PK)
    • 5.5.1. Pharmacokinetics (PK) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Pharmacodynamics (PD)
    • 5.6.1. Pharmacodynamics (PD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Bioavailability
    • 5.7.1. Bioavailability Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Bioequivalence
    • 5.8.1. Bioequivalence Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Biomarker Testing
    • 5.9.1. Biomarker Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Cell-based Assay
    • 5.10.1. Cell-based Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.11. Virology Testing
    • 5.11.1. Virology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.12. Other Tests
    • 5.12.1. Other Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Bioanalytical Testing Services Market: Workflow Estimates & Trend Analysis

  • 6.1. U.S. Bioanalytical Testing Services Market, By Workflow: Segment Dashboard
  • 6.2. U.S. Bioanalytical Testing Services Market, By Workflow Movement Analysis
  • 6.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By Workflow, 2018 - 2030 (USD Million)
  • 6.4. Sample Collection and Preparation
    • 6.4.1. Sample Collection and Preparation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Sample Collection, Handling and Storage
      • 6.4.2.1. Sample Collection, Handling and Storage Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Protein Precipitation
      • 6.4.3.1. Protein Precipitation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Liquid-Liquid Extraction
      • 6.4.4.1. Liquid-Liquid Extraction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Solid Phase Extraction
      • 6.4.5.1. Solid Phase Extraction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Method Development and Validation
    • 6.5.1. Method Development and Validation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Sample Analysis
    • 6.6.1. Sample Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Hyphenated Technique
      • 6.6.2.1. Hyphenated Technique Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Chromatographic technique
      • 6.6.3.1. Chromatographic Technique Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Electrophoresis
      • 6.6.4.1. Electrophoresis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Ligand Binding Assay
      • 6.6.5.1. Ligand Binding Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Mass Spectrometry
      • 6.6.6.1. Mass Spectrometry Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Spectroscopic Techniques
      • 6.6.7.1. Spectroscopic Techniques Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.7.2. Nuclear Magnetic Resonance (NMR)
        • 6.6.7.2.1. Nuclear Magnetic Resonance (NMR) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.7.3. Others
        • 6.6.7.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.8. Genomic and Molecular Techniques
      • 6.6.8.1. Genomic and Molecular Techniques Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.8.2. Polymerase Chain Reaction (PCR)
        • 6.6.8.2.1. Polymerase Chain Reaction (PCR) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.8.3. Next-Generation Sequencing (NGS)
        • 6.6.8.3.1. Next-Generation Sequencing (NGS) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.8.4. Others
        • 6.6.8.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Other Processes
    • 6.7.1. Other Processes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Bioanalytical Testing Services Market: End Use Estimates & Trend Analysis

  • 7.1. U.S. Bioanalytical Testing Services Market, By End Use: Segment Dashboard
  • 7.2. U.S. Bioanalytical Testing Services Market, By End Use: Movement Analysis
  • 7.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
  • 7.4. Pharma & BioPharma Companies
    • 7.4.1. Pharma & BioPharma Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. CDMO
    • 7.5.1. CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. CRO
    • 7.6.1. CRO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Thermo Fisher Scientific, Inc.
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. ICON plc
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Charles River Laboratories International, Inc.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Laboratory Corporation of America Holdings.
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. IQVIA Inc.
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Syneos Health
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. SGS SA
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Intertek Group Plc
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Pace Analytical Services, LLC
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Medpace Holdings, Inc.
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. North America Science Associates Inc. (NAMSA)
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives